Mumbai, January 09, 2020: MSD in India today announced that Rehan A. Khan has been appointed as Managing Director, India Region and will be assuming responsibility from January 13, 2020.

Announcing the leadership appointment, Dorthe Mikkelsen, President Asia Pacific Region, MSD said, “I am thrilled to announce the appointment of Rehan A. Khan as Managing Director for MSD in India. Rehan is an accomplished international leader who has led large and complex multinational businesses, covering India, Greater China, Southeast Asia, and across Asia Pacific with leading multinational companies. His expertise, experience and industry know-how will be invaluable in driving MSD’s business in India and helping achieve our vision for patient access to critical therapies”.

Rehan has over 20 years of in-depth industry experience, including as President of Asia Pacific with an NYSE-listed dialysis services provider with presence across 50 cities in Asia and prior to that as Managing Director of a leading pharmaceutical multinational company in India.

More recently, Rehan was an entrepreneur and Founder of First Penguin Capital, an early stage fund focused on investing in health and consumer tech startups. He was also a board member and advisor to several impact led Private Equity funds and to healthcare companies in Africa, India, and South East Asia.

Rehan is a graduate of the Advanced Management Program at Harvard Business School. He holds a Master of Science degree in Health Sciences from the Harvard-MIT Division of Health Sciences – a joint program between Harvard Medical School and MIT. The program included a 6-month rotation in Oncology at Massachusetts General Hospital. Rehan also has a Master of Business Administration degree from Drexel University and a Bachelor of Science degree from the University of Wisconsin.

About MSD

For more than a century, MSD, a leading global biopharmaceutical company has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardiometabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter, Linkedln and You Tube

Since its existence in the India region, the company has moved quickly in laying the foundation for a business that is differentiated by its focus through launching innovative products relevant to India region. For more information, visit www.msdindia.com